China Biologic Products Inc. vs Tianjin Zhongxin Pharmaceutical Group
A side-by-side look at two Chinese stocks — live quote, valuation, growth, listing venue, dual-listing and delisting status, and the WealthyTec Rank. A factual comparison for orientation, not investment advice.
| Metric | China Biologic Products Inc. CBPO · US (ADR) 77.56 USD | Tianjin Zhongxin Pharmaceutical Group T14.SI · Singapore 1.00 SGD |
|---|---|---|
| Day change | +4.19% | +1.01% |
| Market cap | $2.14B | $7.46B |
| P/E (TTM) | — | — |
| 2y EPS CAGR | — | — |
| WealthyTec Rank | 7.7 | 1.9 |
| Rank within sector | #6 of 31 | #22 of 31 |
| Listing venue | NYSE / NASDAQ (ADR) | SGX |
| Other listings | n/a | n/a |
| Delisting filings | None on record | None on record |
| Sector | Health Care | Health Care |
| Industry | Biotech and Pharma | Biotech and Pharma |
Of the two, China Biologic Products Inc. currently carries the higher WealthyTec Rank (7.7 vs 1.9). The Rank reflects past revenue, earnings and EPS trends only — not valuation, momentum, or the policy and delisting risks every China investor should weigh, and it is not a recommendation to buy, sell or hold either security. See our rank methodology.